Immuno-oncology runs on a comparison between what immune cells do and what they could do if something were changed. Both halves of that comparison depend on the immune cells being representative of a real immune system, which is where primary human material earns its cost over the more convenient alternatives.
Why cell lines answer a different question
Immortalised effector lines are uniform, cheap and always available, which makes them excellent for method development and screening. They are also clonal, adapted to culture and unrepresentative of the variation that exists across actual people.
An effect demonstrated in a single line has been demonstrated in one genetic background. Whether it holds across the population is a question that only primary cells from multiple donors can answer, and it is the question a program eventually has to answer anyway.
The effector populations and what each is for
| Effector | Reads targets via | Best suited to |
|---|---|---|
| CD8+ T cells | Peptide on MHC class I through a rearranged receptor | Antigen-specific killing, epitope work, TCR-directed approaches |
| NK cells | Balance of activating and inhibitory receptors, missing-self | Class I-low targets, ADCC, allogeneic approaches |
| Monocytes and derived macrophages | Innate recognition and phagocytosis | Myeloid-directed approaches, tumor microenvironment models |
| Whole PBMC | All of the above in combination | Systems-level readouts where interaction between populations matters |
Choosing between an isolated effector and whole PBMC is a real decision rather than a convenience. Isolated populations give a clean attribution. Whole PBMC preserves the interactions that make an immune response an immune response, at the cost of knowing which cell did what.
Related product
Leukopak formats. Single-donor starting material, fresh or cryopreserved, with full donor documentation.
Antibody-dependent cytotoxicity deserves its own mention
A substantial part of how therapeutic monoclonal antibodies work in patients runs through NK cells recognising the Fc portion of a bound antibody through CD16 and killing what the antibody has marked. Any program evaluating an antibody without an ADCC-competent effector population is measuring binding rather than function.
This is also why NK-92 and similar lines can mislead in this specific context, since the parent line lacks CD16.
Building an assay that generalises
Use several donors, run separately rather than pooled, and report per donor. Pooling immune cells from different donors additionally introduces allogeneic reactivity between them, which is an activation signal unrelated to your question, as covered in single-donor versus pooled.
Fix the effector-to-target ratio deliberately and report it, since it moves results more than most experimental variables. Rest thawed cells before functional work. And record donor characterization alongside the data so that variance can be attributed rather than explained away.
Sourcing for it
OrganaBio documents isolated effector populations from a single donor program, including NK cells from peripheral blood, cord blood NK cells, pan T cells and monocytes, alongside cryopreserved PBMCs and whole leukopaks. Characterization includes high-resolution NGS HLA typing across six genes and KIR genotyping, and eligible donors can be scheduled for repeat collection so a donor panel can be used consistently across a program.
Frequently asked questions
Why use primary human cells instead of immortalised lines in immuno-oncology?
Lines are clonal, culture-adapted and represent a single genetic background. An effect shown in one line has been shown in one background, whereas the question a program must eventually answer is whether it holds across the population, which requires primary cells from multiple donors.
Should I use isolated effectors or whole PBMC?
Isolated populations give clean attribution of which cell produced the effect. Whole PBMC preserves the interactions between populations that make an immune response coherent, at the cost of that attribution. It is a real experimental decision rather than a convenience.
Why does ADCC require particular attention to the effector source?
Because much of how therapeutic antibodies work in patients runs through NK cells recognising bound antibody via CD16. Evaluating an antibody without an ADCC-competent effector population measures binding rather than function, and the commonly used NK-92 parent line lacks CD16.
Does donor genotype affect immuno-oncology assay results?
Yes. CD16 polymorphism affects ADCC efficiency, and KIR and HLA genotype shape baseline NK behavior against a given target. Running assays across donors of unknown genotype produces spread that is biology rather than noise.
Why should donors not be pooled for these assays?
Beyond hiding between-donor variation, pooling immune cells introduces allogeneic reactivity between donors, which is an activation signal entirely unrelated to the experimental question and cannot be subtracted afterwards.
What should be reported alongside a cytotoxicity result?
The effector-to-target ratio, which moves results more than most variables, the donor identity and characterization, whether cells were rested after thaw, and per-donor rather than averaged values.
How many donors are enough?
Enough to describe a range rather than a point. The purpose of using primary cells is to learn whether an effect generalises, which requires reporting the spread across separately run donors rather than a single averaged figure.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
